Inducción con timoglobulina: ¿incrementa el riesgo hemorrágico en receptores renales sensibilizados? / Could thymoglobulin increase hemorrhagic risk in the perioperative transplantation period of sensitized kidney recipients?

Objetivo: Se ha descrito que la timoglobulina podría aumentar el riesgo de infecciones y neoplasias, en comparación con basiliximab. La leucocitopenia y la trombocitopenia también son más frecuentes en los primeros días tras el trasplante en los pacientes tratados con timoglobulina.Nuestro objetivo fue analizar las complicaciones hemorrágicas en este subconjunto de pacientes.Material y métodos: Se evaluaron las complicaciones hemorrágicas en 515 trasplantes renales realizados en nuestra institución entre 2012 y 2018. Se comparó a los pacientes tratados con timoglobulina (grupo 1, N=91) con los tratados con basiliximab (grupo 2, N=424).Resultados: Encontramos diferencias en cuanto al descenso plaquetario: 95.142,2 (55.339,6) en el grupo 1 y 52.364,3 (69.116,6) en el grupo 2 (p=0,001), número de pacientes con trombocitopenia grave (< 7.5000/mm3) (20,8% vs. 3,7%, p=0,001), número de concentrados de hematíes transfundidos (3,25 [0,572] vs. 2,2 [0,191], p=0,028) y porcentaje de pacientes que requirieron reintervención por sangrado (18,2% vs. 7,7%, p=0,046). En un análisis multivariable de regresión lineal múltiple (la variable dependiente fue el número de concentrado de hematíes transfundidos), solo la edad (OR 0,037, IC del 95%, 0,003-0,070) y el tipo de inmunosupresión (OR 1,592, IC del 95%, 1,38-2,84) tuvieron significación estadística.Conclusiones: El uso de timoglobulina en el período perioperatorio del trasplante podría aumentar las complicaciones hemorrágicas. En nuestra serie, la trombocitopenia grave y el sangrado activo que requirió reintervención, fueron 6 y 2,5 veces más frecuente, respectivamente, en el grupo de pacientes con timoglobulina. En lugar de suspender el uso de este agente inmunosupresor, se podría ajustar la dosis para continuar con el tratamiento.Se debe evaluar el uso de timoglobulina en el postoperatorio de estos pacientes (AU)

Objective: It has been described that thymoglobulin could increase the risk of infections and malignancies, in comparison to basiliximab. Leukopenia and thrombocytopenia are also more common within the first days after transplantation among thymoglobulin patients. Our objective was to analyze bleeding complications in this subset of patients.Material and methods: Bleeding complications were evaluated among 515 renal transplants carried out at our institution between 2012 and 2018. We compared patients treated with thymoglobulin (Group 1, N=91) with those treated with basiliximab (Group 2, N=424).Results: We found differences in platelet decrease:95142.2 (55,339.6) in Group 1 and 52,364.3 (69,116.6) in Group 2 (P=.001), number of patients with severe thrombocytopenia (<75,000/mm3) (20.8% vs. 3.7%, P=.001), number of blood units transfused (3.25 (0.572) vs. 2.2 (0.191, P=.028) and percentage of patients that required surgery due to bleeding (18.2% vs. 7.7%, P=.046). In a multiple lineal regression multivariable analysis (dependent variable was number of blood units transfused), only age [OR 0.037, 95% CI (0.003-0.070)] and type of immunosuppression [OR 1.592, 95% CI (1.38-2.84)] showed statistical significance.Conclusions: The use of thymoglobulin in the perioperative transplantation period could increase bleeding complications. In our series, in the group of patients with thymoglobulin, severe thrombocytopenia was 6 times more frequent, and active bleeding that required surgery was also 2.5 times more frequent. One way to continue with the use of this immunosuppression agent, might be to adjust the dose instead of discontinuing it. The use of thymoglobulin should be a factor to consider in the postoperative period of these patients (AU)

Could thymoglobulin increase hemorrhagic risk in the perioperative transplantation period of sensitized kidney recipients?

OBJECTIVE: It has been described that thymoglobulin could increase the risk of infections and malignancies, in comparison to basiliximab. Leukopenia and thrombocytopenia are also more common within the first days after transplantation among thymoglobulin patients. Our objective was to analyze bleeding complications in this subset of patients. MATERIAL AND METHODS: Bleeding complications were evaluated among 515 renal transplants carried out at our institution between 2012 and 2018. We compared patients treated with thymoglobulin (Group 1, N=91) with those treated with basiliximab (Group 2, N=424). RESULTS: We found differences in platelet decrease: 95,142.2 (55,339.6) in Group 1 and 52,364.3 (69,116.6) in Group 2 (P=0.001), number of patients with severe thrombocytopenia (<75,000/mm3) (20.8% vs. 3.7%, P=0.001), number of blood units transfused (3.25 (0.572) vs. 2.2 (0.191, P=0.028) and percentage of patients that required surgery due to bleeding (18.2% vs. 7.7%, P=0.046). In a multiple lineal regression multivariable analysis (dependent variable was number of blood units transfused), only age [OR 0.037, 95% CI (0.003-0.070)] and type of immunosuppression [OR 1.592, 95% CI (1.38-2.84)] showed statistical significance. CONCLUSIONS: The use of thymoglobulin in the perioperative transplantation period could increase bleeding complications. In our series, in the group of patients with thymoglobulin, severe thrombocytopenia was 6 times more frequent, and active bleeding that required surgery was also 2.5 times more frequent. One way to continue with the use of this immunosuppression agent, might be to adjust the dose instead of discontinuing it. The use of thymoglobulin should be a factor to consider in the postoperative period of these patients.

Cistitis y disfunción vesical asociada al consumo de ketamina / Cystitis and Ketamine Associated Bladder Dysfunction

Objetivos: Analizar la prevalencia de sintomatología del tracto urinario inferior (STUI) en consumidores de ketamina con fines recreativos y valorar su relación con el patrón de consumo. Material y métodos: Valoración de 13 consumidores de ketamina. Se analizó la presencia de STUI, hematuria macroscópica y dolor lumbar. Se registró el patrón de consumo de ketamina: inicio, vía de administración, dosis en el último mes y frecuencia de consumo. Resultados: Seis pacientes (46%) refirieron STUI, con un ritmo diurno medio de micciones cada 42 minutos y nocturia media de 3 episodios, con disuria (100%), urgencia (100%), incontinencia(20%), disminución del caudal (80%), dolor hipogástrico o perineal (80%), hematuria macroscópica (80%) y dolor lumbar bilateral (40%). Los pacientes sintomáticos describieron un consumo medio de ketamina inhalada de 3 g/día (DE 2), el 80% con una frecuencia diaria, y los asintomáticos de 1,03 g/día (DE 0,92) limitado a los fines de semana. El tiempo medio de consumo hasta la aparición de los síntomas fue de 31 meses (DE 16,29). La intensidad de la sintomatología se relacionó con la dosis de ketamina, y mejoró al aumentar la ingesta hídrica. Conclusiones: Parece haber una relación del cuadro con la dosis y la frecuencia de consumo, existiendo factores que refuerzan la hipótesis de que esta acción de la droga se debe a su efecto lesivo sobre el urotelio. Hay que conocer el proceso para identificarlo a tiempo, ya que la única medida efectiva conocida es abandonar el consumo en las fases iniciales (AU)

Objectives: To analyze the prevalence of lower urinary tract symptoms (LUTS) in recreational ketamine users and evaluate its relationship with the consumption pattern. Material and methods: Evaluation of 13 ketamine users. The presence of LUTS, gross hematuria and lumbar spine pain was analyzed. The ketamine usage pattern was recorded: initiation, administration route, dose in the last month and frequency of usage. Results: Six patients (46%) reported LUTS, with daily mean micturations every 42 minutes and night time of 3 episodes, with dysuria (100%), urgency (100%), incontinence (20%), decreased flow (80%), hypogastric or perineal pain (80%), gross hematuria (80%) and bilateral lumbar spine pain (40%). Symptomatic patients described a mean intake of inhaled ketamine of 3 g/day (SD 2), 80% with a daily frequency and the asymptomatic ones of 1.03 g/day (SD 0.92) limited to weekends. The mean consumption time to the appearance of the symptoms was 31 months (SD 16.29). Intensity of the symptoms was related with the ketamine dose and improved on increasing water intake. Conclusions: There seems to be a relationship between the picture with the dose and frequency of consumption, there being factors that reinforce the hypothesis that this action of the drug is due to the harmful effect on the urothelium. The process to identify it on time should be known, since the only known effective measure is to stop the consumption in the initial phases (AU)

[Cystitis and ketamine associated bladder dysfunction]. / Cistitis y disfunción vesical asociada al consumo de ketamina.

OBJECTIVES: To analyze the prevalence of lower urinary tract symptoms (LUTS) in recreational ketamine users and evaluate its relationship with the consumption pattern. MATERIAL AND METHODS: Evaluation of 13 ketamine users. The presence of LUTS, gross hematuria and lumbar spine pain was analyzed. The ketamine usage pattern was recorded: initiation, administration route, dose in the last month and frequency of usage. RESULTS: Six patients (46%) reported LUTS, with daily mean micturations every 42 minutes and nighttime of 3 episodes, with dysuria (100%), urgency (100%), incontinence (20%), decreased flow (80%), hypogastric or perineal pain (80%), gross hematuria (80%) and bilateral lumbar spine pain (40%). Symptomatic patients described a mean intake of inhaled ketamine of 3g/day (SD 2), 80% with a daily frequency and the asymptomatic ones of 1.03 g/day (SD 0.92) limited to weekends. The mean consumption time to the appearance of the symptoms was 31 months (SD 16.29). Intensity of the symptoms was related with the ketamine dose and improved on increasing water intake. CONCLUSIONS: There seems to be a relationship between the picture with the dose and frequency of consumption, there being factors that reinforce the hypothesis that this action of the drug is due to the harmful effect on the urothelium. The process to identify it on time should be known, since the only known effective measure is to stop the consumption in the initial phases.

Sangrado diferido después de nefrectomía parcial. Manejo mediante embolización selectiva / Delayed Bleeding after Partial Nephrectomy. Management with Selective Embolization

Introducción: El sangrado después de una nefrectomía parcial es una complicación con posibles consecuencias graves. Puede ser inmediato o diferido y su incidencia es baja. La causa más frecuente del sangrado diferido es el pseudoaneurisma arterial. La embolización supraselectiva vascular es una opción terapéutica posible que ha demostrado buenos resultados. Objetivo: Evaluar la evolución y el tratamiento del sangrado diferido en nuestra serie de pacientes con nefrectomías parciales. Material y métodos: Realizamos un estudio retrospectivo de nuestra base de datos de nefrectomías parciales. Identificamos los pacientes que presentaron sangrado diferido (después del alta). Se revisó la historia clínica, analizando datos sobre la presentación, el diagnóstico, el tratamiento y la evolución de los pacientes. Resultados: De nuestra serie de nefrectomías parciales tres pacientes presentaron sangrado diferido (1,3%). La clínica se inició después de 17 a 25 días de la cirugía por la aparición de hematuria o dolor lumbar. El diagnóstico se realizó mediante ecografía, TAC abdominal y angiografía renal. En todos los pacientes se diagnosticó un pseudoaneurisma arterial complicado, siendo sometidos a cateterismo arterial renal con embolización selectiva del mismo. La evolución fue correcta en todos los pacientes con control inmediato del sangrado. Documentamos un seguimiento posterior favorable de 61 a 92 meses. Conclusiones: La embolización selectiva vascular es el tratamiento de elección del pseudoaneurisma renal sintomático después de nefrectomía parcial en el paciente hemodinámicamente estable (AU)

Introduction: Bleeding after partial nephrectomy can be immediate or delayed and may have severe consequences. The incidence of this complication is low. The most frequent cause of delayed bleeding is arterial pseudoaneurysm. Superselective embolization is a feasible therapeutic option that has shown good results. Objective: To evaluate treatment and outcomes of delayed bleeding in our series of patients with partial nephrectomy. Material and methods: We performed a retrospective study of our database of partial nephrectomies. Patients who developed delayed bleeding (after discharge) were identified. Clinical histories were reviewed and data on presentation, diagnosis, treatment and outcomes were analyzed. Results: Among our series of patients undergoing partial nephrectomy, three developed delayed bleeding (1.3%). Symptom onset occurred 17 to 25 days after surgery and consisted of hematuria or lumbar pain. Diagnosis was provided through ultrasound, abdominal computed tomography and renal angiography. In all three patients, a complicated pseudoaneurysm was diagnosed and all patients underwent renal artery catheterization with selective renal artery embolization. In all patients, immediate control of bleeding was achieved. Outcome after a follow-up of 61 to 92 months was favorable. Conclusions: Selective vascular embolization is the treatment of choice of renal pseudoaneurysm after partial nephrectomy in hemodynamically stable patients (AU)

[Delayed bleeding after partial nephrectomy. Management with selective embolization]. / Sangrado diferido después de nefrectomía parcial. Manejo mediante embolización selectiva.

INTRODUCTION: Bleeding after partial nephrectomy can be immediate or delayed and may have severe consequences. The incidence of this complication is low. The most frequent cause of delayed bleeding is arterial pseudoaneurysm. Superselective embolization is a feasible therapeutic option that has shown good results. OBJECTIVE: To evaluate treatment and outcomes of delayed bleeding in our series of patients with partial nephrectomy. MATERIAL AND METHODS: We performed a retrospective study of our database of partial nephrectomies. Patients who developed delayed bleeding (after discharge) were identified. Clinical histories were reviewed and data on presentation, diagnosis, treatment and outcomes were analyzed. RESULTS: Among our series of patients undergoing partial nephrectomy, three developed delayed bleeding (1.3%). Symptom onset occurred 17 to 25 days after surgery and consisted of hematuria or lumbar pain. Diagnosis was provided through ultrasound, abdominal computed tomography and renal angiography. In all three patients, a complicated pseudoaneurysm was diagnosed and all patients underwent renal artery catheterization with selective renal artery embolization. In all patients, immediate control of bleeding was achieved. Outcome after a follow-up of 61 to 92 months was favorable. CONCLUSIONS: Selective vascular embolization is the treatment of choice of renal pseudoaneurysm after partial nephrectomy in hemodynamically stable patients.

Nosocomial outbreak of scabies in a hospital in Spain.

An outbreak of scabies occurred in a ward of a local hospital in Barbastro (Huesca, Spain), between November 2002 and January 2003. The outbreak was linked to a patient infested with mites when he was admitted to the ward on 1 November 2002. The first case had onset of symptoms on 5 November and the last one on 5 January 2003. Seventeen cases were reported: 11 healthcare workers (HCWs) and six patients. The outbreak was attributed to a delay in diagnosis, and lack of individual protection measures by caregivers. The use of short-sleeved coats is an habitual risk practice in this ward. Contact with fomites, animals, infested clothes or intimate contact with people other than their usual partners were dismissed as risk factors for the infestation. The different groups of caregivers in this ward presented a similar risk of becoming infested, and the mechanism of transmission was probably person to person contact. The implementation of specific guidelines for scabies prevention and treatment, as well as an active surveillance system, were fundamental to the control of this outbreak.

Staphylococcus aureus meticilin resistente. Un serio peligro para el paciente / Control and surveillance of staphylococcus aureus methycilin resistant

El staphylocccus aureus meticilin resistente (MRSA) puede ser causa de infecciones en pacientes ingresados y por sus múltiples resistencias a antibióticos comportar una dificultad terapéutica. Durante el año 1999 iniciamos este estudio en nuestra Unidad de Cirugía Vascular, planteándonos como prioridad el análisis de la detección de pacientes portadores de MRSA (+) y la efectividad de las medidas de control establecidas. Posteriormente realizamos el análisis y evaluación de las medidas aplicadas en la detección, control y seguimiento de pacientes con MRSA (+) durante el año 2000 en comparación a los resultados obtenidos en el estudio realizado en el año 1999.Constatamos que la correcta utilización de la guía de actuación facilitó el seguimiento, además de la unificación de criterios. Al aplicar la detección precoz basada en la identificación al alta hospitalaria como paciente de riesgo, disminuyeron significativamente los resultados de MRSA (+) en el año 2000. (AU)

[Methicillin-resistant Staphylococcus aureus: a serious problem for the patient]. / Staphylococcus aureus meticilin resistente: un serio peligro para el paciente.

Staphylococcus Aureus Methycilin Resistant (SAMR) can be a cause of infections in patients which are difficult to treat because of their multiple resistances. For this reason, in 1999 we started a study in our Vascular Surgery Unit, to evaluate the effectivity of our stablished control measures to detect patients that were SAMR (+) carriers before discharged. During the year 2000, we repeated the same study and we observed that the precursions use of this control measures, during the first days of admission, decreased the number of SAMR (+) carriers and improved their follow-up.

[Comparative study of Salmonella and Campylobacter infections in Huesca. 1996-1999]. / Estudio comparado de infección por Salmonella y Campylobacter en Huesca. 1996-1999.

BACKGROUND: The Salmonella and Campylobacter genera are the main bacterial agents causing enteritis in humans in the developed countries. The purpose of this paper is to study the descriptive characteristics of the cases of infection by Salmonella and by Campylobacter and to describe their trend and seasonal variance in the province of Huesca for the 1996-1999 period. METHOD: The sources of information were the Hospital Microbiological Laboratories (HML's) which conduct coproculture analyses of both outpatients and inpatients. The municipality is taken as the reference unit for plotting the space distribution. For the study of the trend, a multiplicative determinist model is used for grouping the data into four-week periods. RESULTS: A total of 781 cases of infection by Salmonella and 654 cases of infection by Campylobacter have been included, respectively showing mean annual rates of 95 and 79.5 x 10(5) inhabitants. The enteritis by Campylobacter occurs mainly in children under five years of age (73.4%), as compared to the 35.5% of the cases of salmonellosis. The situation is the reverse in the case of the hospital admission percentages, hospitalization due to salmonellosis hence being nearly five times greater. Both of these genera are of a clear-cut seasonal nature, showing a marked peak in the month of August. CONCLUSIONS: A growing trend in the number of positive isolations for both of these organisms and a clear seasonality in the summertime have been found.